Get the Stockscreener App
88.78
0.50%
0.44
After Hours:
88.78
Edwards Lifesciences Corp stock is traded at $88.78, with a volume of 3.53M.
It is up +0.50% in the last 24 hours and down -1.12% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$88.34
Open:
$89
24h Volume:
3.53M
Relative Volume:
0.86
Market Cap:
$51.17B
Revenue:
$6.30B
Net Income/Loss:
$1.07B
P/E Ratio:
48.23
EPS:
1.8406
Net Cash Flow:
$1.09B
1W Performance:
+3.55%
1M Performance:
-1.12%
6M Performance:
+7.61%
1Y Performance:
+20.38%
1-Day Range:
$88.50
$89.66
1-Week Range:
$84.84
$89.70
52-Week Range:
$72.30
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, MDT, SYK, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
88.78 | 48.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
103.69 | 176.41B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
90.77 | 116.35B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.09 | 105.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.92 | 62.29B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Truist raises Edwards Lifesciences target to $95 - scanx.trade
Wall Street Zen Upgrades Edwards Lifesciences (NYSE:EW) to "Buy" - MarketBeat
Insider Daniel Lippis Sells 619 Shares of Edwards Lifesciences C - GuruFocus
Edwards Lifesciences CVP Daniel Lippis sells $54,168 in stock By Investing.com - Investing.com Australia
Edwards Lifesciences stock up 726% in 15 years, beating market - scanx.trade
Why Edwards Lifesciences (EW) Stock Is Down Today - Quiver Quantitative
Edwards Lifesciences, Medtronic score CMS win for TAVR - MassDevice
CMS TAVR changes, a boon for Edwards - BioWorld News
Edwards Lifesciences stock price target maintained at $85 by Canaccord - Investing.com Canada
Engineers Gate Manager LP Sells 81,590 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Comments on TAVR National Coverage Decision - Finviz
Edwards Lifesciences maintains 2026 guidance after CMS TAVR NCD - scanx.trade
Edwards Lifesciences stock edges higher after raised 2026 revenue guidance - ad-hoc-news.de
Edwards Lifesciences stock heads into the open after a mild decline - ad-hoc-news.de
EW Stock Quote Price and Forecast - CNN
Can Edwards Lifesciences (NYSE:EW) Withstand Market Pressure? - Kalkine Media
Edwards Lifesciences Corporation $EW Stock Holdings Lifted by California State Teachers Retirement System - MarketBeat
Amundi Decreases Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) Institutional Ownership 2026 $EW - marketbeat.com
Edwards Lifesciences stock heads into the open after a 3.2 percent drop - ad-hoc-news.de
Edwards Lifesciences Corp (EW) Stock Down 3.5% -- Now Undervalued? GF Score: 95/100 - GuruFocus
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Edwards Lifesciences Stock Underperforming the Dow? - Yahoo Finance
How MNCs co-innovate with Singapore enterprises to drive productivity and save costs - edb.gov.sg
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases New Shares in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound (NYSE:EW) - Seeking Alpha
Azimuth Capital Investment Management LLC Decreases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
B. Metzler seel. Sohn & Co. AG Lowers Position in Edwards Lifesciences Corporation $EW - MarketBeat
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
EW Stock Price and Chart — NYSE:EW - TradingView
Nykredit A S Makes New $20.64 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit 2026 - BioSpace
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit - marketscreener.com
Empowered Funds LLC Buys New Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) SVP, Corporate Controller Andrew Dahl Sells 544 Shares - GuruFocus
NS Partners Ltd Reduces Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Van ECK Associates Corp Decreases Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences SVP sells $49,533 in stock By Investing.com - Investing.com Nigeria
Edwards Lifesciences (NYSE:EW) SVP Sells 544 Shares of Stock - marketbeat.com
Edwards Lifesciences SVP sells $49,533 in stock - Investing.com
Breadth Narrows, Software Shines; Fortinet, Edwards Lifesciences, UBS In FocusVideoIBD - Investor's Business Daily
Edwards Lifesciences (NYSE: EW) exec plans $49K stock sale - Stock Titan
Edwards Lifesciences strategy VP will leave next year - MassDevice
Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock - Barchart.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
24,532 Shares in Edwards Lifesciences Corporation $EW Purchased by Kingsview Wealth Management LLC - MarketBeat
19,972 Shares in Edwards Lifesciences Corporation $EW Purchased by United Capital Financial Advisors LLC - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Alyeska Investment Group L.P. - MarketBeat
Wellington Management Group LLP Lowers Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Jefferies Financial Group Inc. Invests $3.58 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):